Every Form 4 that Neurogene, Inc. (NGNE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NGNE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NGNE filings page.
Neurogene Inc. President and CFO Christine Mikail Cvijic reported open-market sales of 4,800 shares of common stock under a pre-arranged Rule 10b5-1 trading plan. The sales occurred on two days at weighted average prices around the mid-$36 range.
After these transactions, she reports ownership of 84,040 shares, which includes 10,635 restricted stock units scheduled to vest on March 13, 2027, 13,533 restricted stock units vesting in equal installments on March 26, 2027 and March 26, 2028, and 22,000 restricted stock units vesting annually from February 20, 2027 through February 20, 2029. The filing notes that following completion of these sales she no longer holds any shares jointly with her spouse.
Neurogene Inc. director and President/CFO Christine Mikail Cvijic reported open-market sales of 4,800 shares of common stock. The sales occurred on July 1–2, 2026 in three tranches at weighted average prices around $34–$35 per share.
The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 18, 2025, and involved shares held jointly with her spouse. Following these sales, she continues to directly hold 88,840 shares, along with additional unvested restricted stock units scheduled to vest between 2027 and 2029.
Neurogene Inc. director Woods Keith received a stock option grant to acquire 15,400 shares of common stock at an exercise price of $32.30 per share. The option was granted as a compensation award and vests in equal monthly installments through January 16, 2027, conditioned on continued service. Following this grant, Woods holds 15,400 stock options expiring on January 16, 2034.
Neurogene Inc. director Keith Woods received a fully vested stock option grant covering 7,700 shares of common stock. The option has an exercise price of $42.59 per share and expires on June 14, 2034. Following this award, he holds 7,700 stock options directly.
Neurogene Inc. director Keith Woods received a fully vested non-qualified stock option grant. The award covers 12,050 options, each giving the right to buy one share of common stock at an exercise price of $20.40 per share, expiring on June 12, 2035. Following this compensation-related grant, Woods holds 12,050 derivative securities directly, with no open-market share purchases or sales reported in this filing.
Neurogene Inc. director and President/CFO Christine Mikail Cvijic reported two open‑market sales of common stock totaling 9,600 shares on May 6, 2026. The transactions were executed at weighted average prices of $30.0732 and $32.4358 per share.
According to a footnote, these sales were made under a Rule 10b5‑1 trading plan adopted on August 18, 2025, and the shares sold were held jointly with her spouse, David Cvijic. After the transactions, she directly holds 93,640 shares, including 10,635 restricted stock units vesting on March 13, 2027; 13,533 restricted stock units vesting in equal installments on March 26, 2027 and March 26, 2028; and 22,000 restricted stock units vesting annually on February 20, 2027, 2028 and 2029. Of the remaining shares, 9,600 are held jointly with her spouse.
Neurogene Inc. reported that Chief Commercial Officer Christina Shafer received a grant of non-qualified stock options covering 120,000 shares of common stock at an exercise price of $28.94 per share. One quarter of these options will vest on April 20, 2027, with the remaining three quarters vesting in equal monthly installments on the 20th of each month through April 20, 2030, contingent on her continued service. Following this grant, she holds 120,000 derivative securities directly.
Neurogene Inc. President and CFO Christine Mikail Cvijic reported an open-market sale of 2,558 shares of common stock on March 26, 2026 at a weighted average price of $21.6247 per share. According to the disclosure, this sale was mandatory and executed by the company solely to cover her tax withholding obligation arising from the partial vesting of a Restricted Stock Unit (RSU) award, with no election made by her.
After this transaction, she directly holds 103,240 shares, which include multiple unvested RSU grants: 10,635 RSUs granted on March 13, 2024 that vest on March 13, 2027; 13,533 RSUs granted on March 26, 2025 that vest in equal annual installments on March 26, 2027 and March 26, 2028; and 22,000 RSUs granted on February 20, 2026 that vest in equal annual installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly with her spouse.
Neurogene Inc. director and CEO Rachel McMinn reported an automatic sale of common stock tied to RSU vesting. On March 26, 2026, 3,352 shares of Neurogene common stock were sold at a weighted average price of $22.0749 per share to cover tax withholding from a partially vested Restricted Stock Unit award. The award agreement required the company to sell enough shares to satisfy tax obligations, with no election by McMinn, making this a mechanistic tax-related sale rather than a discretionary open-market trade. After the transaction, she directly held 1,344,307 shares of common stock, along with additional restricted stock units scheduled to vest between February 2027 and February 2029.
Neurogene Inc. Chief Medical Officer Julie Jordan reported an open-market sale of 828 shares of Common Stock at a weighted average price of $21.8932 per share. According to the disclosure, this sale was mandatory and executed solely to cover tax withholding arising from a partially vested restricted stock unit (RSU).
After this transaction, Jordan reports holding 12,472 shares, including 5,600 RSUs that vest in equal annual installments on March 26, 2027 and March 26, 2028, and 4,900 RSUs that vest in equal annual installments on February 20, 2027, February 20, 2028 and February 20, 2029, all subject to continued service.
Neurogene Inc. Chief Scientific Officer Stuart Cobb reported selling 6,797 shares of common stock in three open-market transactions on March 13, 2026. The sales occurred at prices reported as weighted averages of $20.41, $21.34, and $22.08, with detailed ranges noted in the disclosure.
The filing states these trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on February 6, 2025. After these transactions, Cobb directly holds 30,497 shares, which include restricted stock units scheduled to vest between 2026 and 2029, subject to continued service.
Neurogene Inc. President and CFO Christine Mikail Cvijic reported automatic sales of common stock tied to a restricted stock unit (RSU) vesting. On March 13, 2026, a total of 4,045 shares of Neurogene common stock were sold in three open-market transactions at weighted average prices of $20.4224, $21.2451, and $22.0195 per share.
According to the disclosure, these sales were executed under the RSU award agreement, which requires the company to sell enough shares to cover the executive’s tax withholding obligations from the March 12, 2025 vesting event, with no election by the executive. After the sales, Cvijic directly owned 105,798 common shares, in addition to multiple unvested RSU awards scheduled to vest between 2026 and 2029.
Neurogene Inc. President and CFO Christine Mikail Cvijic reported an open‑market sale of 4,800 shares of common stock on February 27, 2026 under a pre‑arranged Rule 10b5‑1 plan adopted on August 18, 2025. The weighted average sale price was $25.1096 per share, with individual trades ranging from $25.00 to $25.325. After this transaction, she and her spouse jointly hold 109,843 shares, including 21,269 restricted stock units from a March 13, 2024 grant, 20,300 restricted stock units from a March 26, 2025 grant, and 22,000 restricted stock units from a February 20, 2026 grant, plus 19,200 shares held jointly.
Neurogene Inc. reported that Chief Scientific Officer Cobb Stuart acquired 16,500 shares of common stock in the form of restricted stock units. These units were granted at no cash cost and will vest in three equal annual installments starting on February 20, 2027, contingent on continued service.
After this grant, Stuart holds 37,294 restricted stock units in total, reflecting multiple prior awards. According to the footnotes, these earlier grants vest annually from March 13, 2025 through March 13, 2027 and from March 26, 2026 through March 26, 2028, with the new grant vesting through February 20, 2029.
Neurogene Inc. reported that Chief Medical Officer Jordan Julie acquired equity awards on February 20, 2026. The awards include a stock option for 29,600 shares of common stock and 4,900 restricted stock units, both subject to multi‑year vesting tied to continued service.
Neurogene Inc. reported that President and CFO Christine Mikail Cvijic received new equity awards. On February 20, 2026 she was granted a stock option for 131,900 shares of common stock at an exercise price of $0.00 per share. One quarter of this option vests on the first anniversary of the grant, with the remaining three quarters vesting in equal monthly installments through the fourth anniversary, conditioned on continued service. She also received 22,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date, also subject to continued service. Following these awards, her directly held common stock position is 114,643 shares, including previously granted restricted stock units and 24,000 shares held jointly with her spouse.
Neurogene Inc. reported that Chief Executive Officer and director Rachel McMinn acquired new equity awards. On February 20, 2026, she received a stock option covering 155,100 shares of common stock at an exercise price of $0.00 per share, vesting over four years as described in the filing. She also received 25,900 restricted stock units, vesting in three equal annual installments starting on the first anniversary of the grant date, contingent on continued service. After the reported common stock award, McMinn beneficially owned 1,347,659 shares of common stock directly, including previously granted restricted stock units, and the filing notes an earlier administrative understatement of her reported holdings that is now corrected.
PALEKAR ROHAN reported acquisition or exercise transactions in this Form 4 filing.
Neurogene Inc. director Rohan Palekar received a grant of 12,050 non-qualified stock options on February 20, 2026. These options give him the right to buy Neurogene shares if and when they vest.
The award vests in equal monthly installments over one year, with 1/12 of the options vesting each month starting March 20, 2026 and becoming fully vested by February 20, 2027, as long as he continues providing service to the company on each vesting date.
Neurogene Inc. director Robert Baffi received a grant of 12,050 non-qualified stock options on February 20, 2026. The options have a $0.00 exercise price and vest in equal 1/12 installments each month from March 20, 2026 through February 20, 2027, contingent on continued service.
Neurogene Inc. director Sarah B. Noonberg received a grant of non-qualified stock options for 12,050 shares at an exercise price of $0.00 per share. The option vests in equal monthly installments of 1/12 from March 20, 2026 until fully vested on February 20, 2027, conditioned on continued service.
Freedland Cory S. reported acquisition or exercise transactions in this Form 4 filing.
Neurogene Inc. director Cory S. Freedland reported receiving a grant of 12,050 non-qualified stock options. The options were awarded at a disclosed price of $0.0000 per option and are held directly.
The option grant vests in equal 1/12 monthly installments starting on March 20, 2026, and will be fully vested on February 20, 2027, as long as Freedland continues providing service to Neurogene on each vesting date.
Neurogene Inc. director Woods Keith reported receiving a grant of non-qualified stock options covering 12,050 shares of Neurogene common stock. This is classified as an acquisition of derivative securities as a grant or award, rather than an open-market purchase or sale.
According to the disclosure, the option vests in equal monthly installments of 1/12 of the total shares beginning on March 20, 2026, and will be fully vested by February 20, 2027. Vesting is conditioned on Keith continuing to provide services to Neurogene on each vesting date, meaning the award is tied to ongoing service over this roughly one-year period.